Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) have been given a consensus recommendation of “Reduce” by the eight brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and seven have given a hold recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $23.33.
A number of research analysts recently commented on AMPH shares. Wall Street Zen upgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 9th. Barclays boosted their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 18th. Weiss Ratings upgraded Amphastar Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. Piper Sandler decreased their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Finally, Wells Fargo & Company lifted their price target on Amphastar Pharmaceuticals from $20.00 to $25.00 and gave the company an “equal weight” rating in a research report on Friday, November 6th.
Read Our Latest Research Report on AMPH
Amphastar Pharmaceuticals Stock Performance
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.86 by $0.28. The firm had revenue of $207.61 million for the quarter, compared to analysts’ expectations of $197.52 million. Amphastar Pharmaceuticals had a net margin of 13.27% and a return on equity of 15.31%. Sell-side analysts predict that Amphastar Pharmaceuticals will post 2.68 earnings per share for the current fiscal year.
Insider Buying and Selling at Amphastar Pharmaceuticals
In related news, EVP Rong Zhou sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total transaction of $239,400.00. Following the completion of the transaction, the executive vice president owned 169,203 shares of the company’s stock, valued at $4,050,719.82. This trade represents a 5.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO William Peters sold 12,631 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $28.99, for a total value of $366,172.69. Following the transaction, the chief financial officer directly owned 167,076 shares in the company, valued at approximately $4,843,533.24. The trade was a 7.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 45,957 shares of company stock valued at $1,232,836. Insiders own 29.60% of the company’s stock.
Hedge Funds Weigh In On Amphastar Pharmaceuticals
Large investors have recently made changes to their positions in the business. Eurizon Capital SGR S.p.A. bought a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $33,000. Nisa Investment Advisors LLC lifted its stake in Amphastar Pharmaceuticals by 183.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,422 shares of the company’s stock valued at $37,000 after purchasing an additional 920 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Amphastar Pharmaceuticals during the second quarter valued at approximately $39,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Amphastar Pharmaceuticals during the third quarter valued at approximately $56,000. Finally, State of Wyoming bought a new stake in Amphastar Pharmaceuticals during the second quarter worth approximately $142,000. Institutional investors own 65.09% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets generic and proprietary medicines, with a focus on products that can be technically challenging to produce. Its offerings include injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients. The company’s products include treatments and emergency medicines such as enoxaparin, glucagon and epinephrine products. Amphastar also markets BAQSIMI, a nasal powder used to treat severe low blood sugar, and Primatene MIST, an over-the-counter asthma inhaler.
Featured Stories
- Five stocks we like better than Amphastar Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
